Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00482677 : Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
PhasePhase 3
AgesMin: 65 Years Max: N/A
Eligibility
DISEASE CHARACTERISTICS:

- Histopathologically confirmed glioblastoma multiforme

- Grade IV disease by WHO classification

- Newly diagnosed disease

- Initial diagnostic surgery or biopsy performed within the past 4 weeks

- Not a candidate for standard radiotherapy (60Gy/30 fractions over 6 weeks) in
combination with temozolomide

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Absolute granulocyte count ? 1,500/mm³

- Platelet count ? 100,000/mm³

- Creatinine ? 1.5 times upper limit of normal (ULN)

- Bilirubin ? 1.5 times ULN

- ALT and AST < 2.5 times ULN

- No known hypersensitivity to temozolomide or compounds with similar chemical
composition to temozolomide

- No history of other malignancies except adequately treated nonmelanoma skin cancer,
curatively treated in situ cancer of the cervix, or other curatively treated solid
tumors with no evidence of disease for at least 5 years

- No serious active infection (e.g., wound infection requiring parenteral antibiotics)
or other serious underlying medical conditions that would preclude study treatment

- No other condition (e.g., psychological or geographical) that would preclude study
compliance

PRIOR CONCURRENT THERAPY:

- No prior chemotherapy

- No prior radiotherapy

- No prior or concurrent investigational therapy

- No concurrent surgical procedures for tumor debulking

- No concurrent stereotactic boost radiotherapy

- No other concurrent chemotherapy, immunotherapy, or biological therapy

- No concurrent epoetin alfa

- Concurrent corticosteroids allowed provided the patient has been on a stable or
decreasing dose for at least 14 days
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT00482677      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740